- Home
- GSIW vs ATOS Comparison
GSIW vs ATOS Comparison
Compare GSIW & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSIW | ATOS |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.5M | 36.2M |
| IPO Year | 2022 | 2010 |
Fundamental Metrics
Financial Performance| Metric | GSIW | ATOS |
|---|---|---|
| Price | $35.33 | $2.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $23.00 |
| AVG Volume (30 Days) | 5.4K | ★ 207.1K |
| Earning Date | 08-04-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,758.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.05 | $0.53 |
| 52 Week High | $38.55 | $7.56 |
Technical Indicators
Market Signals| Indicator | GSIW | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 63.78 | 15.30 |
| Support Level | $0.11 | $0.63 |
| Resistance Level | $36.90 | $6.18 |
| Average True Range (ATR) | 3.08 | 0.24 |
| MACD | -0.03 | -0.27 |
| Stochastic Oscillator | 73.00 | 1.85 |
Price Performance
Historical ComparisonAbout GSIW Garden Stage Limited
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.